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A PUSH FOR CHANGE: A REVIEW OF THE USE OF ADVANCED 
NEUROIMAGING IN THE URGENT EVALUATION OF ACUTE STROKE, 
AND THE IMPACT ON CLINICAL GUIDELINES 
DARRYL E. MCFARLAND 
ABSTRACT 
In 1996, the United States Food and Drug Administration officially approved the 
use of intravenous recombinant tissue-type plasminogen activator for treatment of acute 
ischemic stroke, with the requirement that a baseline computed tomography (CT) scan be 
performed to rule out acute intracerebral or subarachnoid hemorrhage. Today, the 
American Heart Association (AHA) Stroke Council acknowledges magnetic resonance 
imaging (MRI) as more sensitive to the detection of ischemia, and yet, guidelines 
released by the group suggest that either CT or MRI may serve as the primary, 
hyperacute imaging modality. The AHA recommends that for most cases, non-contrast-
enhanced CT scans provide sufficient information for medical management decisions. A 
systematic review of published literature was conducted to compare current capabilities 
of CT and MRI in an effort to determine which imaging modality should be used in the 
setting of acute ischemic stroke. Current research indicates that MRI is comparable to CT 
in the detection of acute hemorrhage, but superior in the detection of acute ischemia. In 
addition, MRI has demonstrated the ability to not only identify suitable patients for 
treatment, but also identify patients whose treatment would be unnecessary and 
potentially dangerous. Therefore, the hope is that clinical guidelines, like those released 
by the AHA Stroke Council, will be modified to promote MRI as the primary imaging 
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modality. A modification to the major clinical guidelines will initiate a change in the 
approach of acute stroke evaluation across all clinical stroke centers.  
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INTRODUCTION 
 
Stroke is a tragic neurologic deficit that dramatically impacts patients and their 
families, and places a tremendous financial burden on all involved. For decades, stroke 
was the third-leading cause of death in the United States (US), but in 2008, it dropped to 
fourth1,2. Despite the decreased rank, roughly 795,000 people each year have a stroke in 
the US, which directly results in almost 130,000 deaths2,3; this equates to someone in the 
US having a stroke every 40 seconds, and a stroke-related death every 4 minutes2,4. In 
2009, stroke accounted for 5.2% of the total deaths in the US alone4. From 1999 to 2009, 
the annual death rate due to stroke in the US decreased by 36.9%, with the southeastern 
region maintaining the highest prevalence of stroke4, as highlighted by Figure 1. 
 
Figure 1: Prevalence of Stroke Across the United States (2007-2009)2. Reported 
stroke deaths vary by geography, with the highest prevalence in the southeastern US. 
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Stroke is a leading cause of disability, accounting for more than 2% of all health-
related expenditures2.  In 2009 alone, the combined direct and indirect cost of stroke was 
$38.6 billion2. The direct cost of non-nursing home stroke care equated to more than 
10.7% of the Medicare budget2,5,6, but the long-term costs of nursing home care are even 
higher. In addition, the indirect costs due to premature mortality and the loss of 
productivity in recovering stroke survivors is more than all of the direct costs combined7. 
From 1995 to 2005, the medical expenses associated with stroke increased by an average 
of only 2% per year8. However, this rate is projected to increase substantially in the next 
several decades due to an aging US population and the direct association between age and 
the occurrence of stroke2. 
Ovbiagele et al. took the first step in addressing this demographic reality by 
analyzing the projected future prevalence of stroke, as well as the associated costs in the 
US.  Such projections were based on age groups (18-44, 45-64, 65-79, & ≥80 years), sex 
(men & women), and race/ethnicity (white non-Hispanic, black non-Hispanic, Hispanic, 
& other). By 2030, Ovbiagele et al. estimated that an additional 3.4 million people will 
suffer from a stroke each year, which will correlate to nearly 4% of the total US 
population having a stroke9. The greatest projected increase in stroke prevalence is 
expected to be among white Hispanic men (29.07% relative change, 2012-2030)9. As a 
result of an increased rate of occurrence, the total annual cost associated with stroke is 
anticipated to increase to $240.67 billion, with the 65-79 year-old age group responsible 
for the largest increase in medical costs9, as highlighted by Figure 2. With these eye-
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opening projections, it is essential that health professionals improve cerebrovascular 
disease prevention, diagnosis, and treatment in order to minimize stroke-related costs. 
 
Figure 2: Projected Total Annual Cost of Stroke9. From 2012 to 2030, the projected 
total indirect and direct costs (in billions, 2010) associated with stroke, based on age 
groups. 
 
Classification of Stroke 
In 1970, the World Health Organization (WHO) introduced the following 
definition for stroke, which is still in use today: “… rapidly developing clinical signs of 
focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to 
death, with no apparent cause other than that of vascular origin”10. Such disturbances in 
the central nervous system (CNS) are due to a disruption of the blood supply to the brain 
and are classified as hemorrhagic or ischemic strokes. For clinical distinction between 
stroke types, a transient ischemic attack (TIA) is a temporary interruption of blood 
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supply, resulting in an episode of focal loss of cerebral function lasting <24 hours, but 
leaving no persistent neurological deficit11. 
 
Hemorrhagic Stroke 
Hemorrhagic strokes, accounting for roughly 13% of all stroke cases, occur when 
a damaged or weakened blood vessel ruptures and bleeds into the surrounding brain 
tissue12. The two types of weakened vessels that can rupture are aneurysms and 
arteriovenous malformations (AVMs). As seen in Figure 3, an aneurysm (Greek for 
‘dilation’) is a localized, balloon-like bulge in the wall of a blood vessel, while an AVM 
is an abnormal accumulation of improperly formed blood vessels12,13. Aneurysms and 
AVMs commonly rupture as a result of uncontrolled hypertension12. Complications arise 
from hemorrhagic strokes when the accumulating blood compresses and damages the 
surrounding brain tissue and vasculature. Diagnosis of hemorrhagic stroke can be further 
broken down into either a subarachnoid hemorrhage or an intracerebral hemorrhage. 
 
Figure 3: Cerebral Aneurysm13 and Arteriovenous Malformation14. The image on the 
left demonstrates an aneurysm, with the characteristic outcropping of the blood vessel, 
while the image on the right demonstrates an AVM, with the characteristic collection of 
abnormally formed blood vessels. 
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Subarachnoid hemorrhage (SAH), as highlighted in Figure 5, is defined as 
extracerebral bleeding in the subarachnoid space, an area located between the arachnoid 
mater and the pia mater surrounding the brain and spinal cord13. SAH comprise anywhere 
from 1-7% of all strokes15, with roughly 80% of cases resulting from a ruptured 
aneurysm13.  Recent population-based studies have found that SAH is associated with a 
20-45% mortality rate16-18 and a 10% severe disability rate18. However, it should be noted 
that more comprehensive assessments have demonstrated elevated projections of social, 
cognitive, and health disability19,20. 
A number of symptoms are associated with the onset of a SAH, including a severe 
headache with rapid onset, altered mental status, vomiting and occasional seizures. The 
most characteristic symptom of SAH is a sudden headache, occurring in nearly a third of 
patients, with roughly 75% of these individuals reporting the onset occurring within a few 
seconds21-23. However, of all cases involving a severe headache with rapid onset, SAH 
accounts for only 10%23. Therefore, the diagnosis of SAH is not based on just the clinical 
symptoms, but rather by the presence of blood in the subarachnoid space. The presence of 
this blood is confirmed by neuroimaging or by sampling the cerebrospinal fluid (CSF), 
which circulates within the subarachnoid space. As highlighted in Figure 4, visual 
inspection of CSF can determine the presence of xanthochromia, a yellowish metabolite 
that results when the heme of red blood cells breaks down in the subarachnoid space24. 
Dupont et al. reported 93% sensitivity and 95% specificity25 in utilizing CSF for the 
detection of SAH, while Arora et al. reported 47.3% specificity26. However, non-invasive 
neuroimaging, specifically computed tomography (CT) and magnetic resonance imaging 
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(MRI), remain the diagnostic technique of choice for detecting SAH. An evaluation of 
these two neuroimaging techniques will be discussed in a later section. 
 
Figure 4: Xanthochromia within Cerebrospinal Fluid21. After centrifugation, 
cerebrospinal fluid (right) demonstrates a yellowish color in comparison to water (left), 
indicating the presence of hemorrhage within the subarachnoid space. 
 
Unlike SAH, intracerebral hemorrhage (ICH), as highlighted in Figure 5, is 
defined as intracerebral bleeding, or bleeding within the tissue of the brain. The etiology 
of ICH can be separated into two categories: primary, which is associated with 
hypertension and accounts for about 80% of ICH cases, and secondary, which is 
associated with coagulopathies, AVMs, vasculopathies, or intracranial tumors, and 
accounts for the remaining 20% of ICH cases27.  Despite ICH accounting for only 10% of 
all strokes28, it is viewed as one of the most disabling forms of stroke. At 30 days, ICH 
alone has a 40% case-fatality rate29,30, and of those who survive, only 20% will regain 
full-functional independence31. 
Like SAH, ICH is usually accompanied by a severe headache with rapid onset, 
nausea, vomiting, and decreased level of consciousness. ICH classically presents with 
sudden onset of a focal neurological deficit, with this deficit corresponding with the site 
of parenchymal hemorrhage. Thus, ataxia, which is a lack of voluntary coordination of 
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muscle movements, is the symptom initially noted in a cerebellar hemorrhage, while 
weakness is typically noted in a basal ganglia hemorrhage. In roughly 50% of ICH cases, 
there is a notable decreased level of consciousness, as well as an early progression of 
neurologic deficits, with ongoing bleeding and enlargement of the hematoma accounting 
for this progression32-34.  However, a diagnosis of ICH cannot be determined just based on 
these symptoms. The symptoms of SAH and ICH overlap too much to distinguish 
between the two based on clinical observation alone. In addition, patients with an 
ischemic stroke can also present with the symptoms of headache and vomiting. Despite 
these symptoms being observed three times more often in ICH cases35,36, ischemic stroke 
must also remain as a differential diagnosis. Therefore, the utilization of non-contrast 
head CT or brain MRI is essential to determining the correct diagnosis, in order to assist 
with both short- and long-term medical management decisions. 
 
Figure 5: Intracerebral and Subarachnoid Hemorrhage28. An intracerebral 
hemorrhage (upper right) is characterized by bleeding within the brain, whereas a 
subarachnoid hemorrhage (lower right) is characterized by extracerebral bleeding within 
the subarachnoid space. 
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Ischemic Stroke 
Accounting for 87% of all stroke cases, an ischemic stroke occurs when a blood 
vessel becomes obstructed, inhibiting the blood supply to a vascular territory of the 
brain37. There are several different physiological causes, including thrombotic and 
embolic etiologies that can lead to vascular occlusion and subsequent ischemic stroke. 
The most common problem is narrowing of the arteries within the neck or brain, typically 
caused by gradual cholesterol deposition within the walls of an artery, a process known 
as atherosclerosis. As the artery narrows, red blood cells and clotting factors can collect 
and form a local blood clot, known as a thrombus, which can occlude the blood vessel at 
the site of narrowing, as highlighted in Figure 6. An artery within the brain can also be 
obstructed by an embolus, or a blood clot that forms at another location within the 
circulatory system, which can then dislodge and become trapped in either a narrowed 
vessel or a vessel too small to let the clot pass, as indicated in Figure 6. The most 
common site of embolic clot formation is within the heart, where atrial fibrillation, heart 
attack, and abnormalities of the heart valves create clot-forming conditions. In addition, 
systemic hypoperfusion or venous thrombosis can decrease the amount of blood supplied 
to the brain. Systemic hypoperfusion occurs when the heart is unable to pump an 
adequate amount of blood to all parts of the body, while venous thrombosis involves a 
clot obstructing blood flow in the vessels that drain blood from the brain38. If there is no 
apparent explanation for the cause of the ischemic event, the stroke is classified as 
cryptogenic39,40, which has been reported to account for 30-40% of all stroke cases39-41. 
Although, there have been studies that could provide insight on the potential etiology of 
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cryptogenic strokes. These studies have specifically focused on patients with a fetal 
cardiac shunt that fails to close, known as a patent foramen ovale, and an atheroma of the 
aortic arch42. 
 
Figure 6: Thrombotic43 and Embolic Ischemic Strokes44. The thrombotic stroke (left), 
involves the formation of a thrombus around a narrowed, atherosclerotic artery, which 
deprives the brain of essential oxygen and nutrients, resulting in damaged tissue 
(shadowed region). The embolic stroke (right) involves the formation of an embolus, 
which dislodged and became trapped at a junction to smaller vessels. 
 
As knowledge surrounding the subtypes of ischemic stroke has grown, several 
classification systems have emerged. One classification scheme arose after a population-
based study on first-time stroke, known as the Oxfordshire Community Stroke Project 
(OCSP). Bamford et al. proposed four subgroups of cerebral infarction based on clinical 
features: lacunar infarcts (LACI), partial anterior circulation infarcts (PACI), total 
anterior circulation infarcts (TACI), and posterior circulation infarcts (POCI)45. These 
subgroups are easily defined, and therefore, allow for a rapid and reliable way to 
categorize patients with acute ischemic stroke. The OCSP scheme also demonstrated 
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consistent inter-observer classification, while reliably predicting infarct location and size 
on CT, mortality rate, and degree of functional recovery46-55. However, Asdaghi et al. 
prospectively assessed the reliability of the OCSP classification scheme in predicting the 
pattern of lesions on MRI and concluded that the OCSP scheme poorly differentiates 
between subcortical and small cortical infarcts56. 
Another stroke classification system, based on etiology, was developed for the 
Trial of Org 10172 in Acute Stroke Treatment (TOAST)57, a placebo-controlled, 
randomized, blinded study. As indicated in Appendix I, Adams et al. proposed a 
classification system based on five categories: large-artery atherosclerosis, 
cardioembolism, small-artery occlusion (lacune), stroke of other determined etiology, and 
stroke of undetermined etiology57. This classification system was designed for acute 
ischemic stroke clinical trials, where multiple institutions collaborate and uniformity of 
diagnosis between centers is essential. According to Tuttolomondo et al., TOAST is a 
“classification with clinical, pathophysiological, anatomical, and instrumental basis that 
is easily applicable and widely validated”58. However, as this classification system gained 
popularity, it became apparent that amendments were necessary, and the modified 
TOAST system emerged, which improved the criteria in terms of reliability and 
accuracy59. Despite this modification, the new TOAST system, while still based upon the 
‘most likely cause of stroke,’ continues to ignore coexisting etiologies. Any patient with 
two or more identified etiologies is still classified under “undetermined etiology,” which 
inherently leads to a disproportionate amount of patients falling under this category, even 
though the probable causes of stroke are identifiable60. 
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In response to the criticism of the modified TOAST classification system, 
Amarenco et al. developed a new system, known as the A-S-C-O (phenotypic) 
classification of stroke, which incorporates both the stroke etiology and any pre-existing 
diseases60. Within this classification system, each patient is evaluated and graded for the 
following phenotypes: atherosclerosis, small-vessel disease, cardiac source, and other 
cause. These four phenotypes each receive one of the following grades: zero for when 
disease is completely absent, one for ‘definitely a potential cause of the index stroke,’ 
two for ‘causality uncertain,’ three for ‘unlikely a direct cause of the index stroke, but 
disease is present,’ and nine for insufficient workup60. In addition, the diagnostic 
evidence receives a grade of either A, B, or C, where A represents evidence acquired by a 
gold-standard diagnostic technique, B for evidence acquired from a less sensitive 
technique, and C for evidence acquired in the absence of diagnostic criteria60. As 
summarized in Appendix II, the ASCO classification scheme is much more extensive 
than TOAST, but in a comparative study, Shang et al. concluded that there was a high 
level of agreement, with the exception of the ‘undetermined’ category, between the two 
classification schemes61. However, when ASCO-1 was applied, there was no significant 
reduction of patients identified under ‘undetermined’ etiology in comparison to modified 
TOAST61. In the interest of further distinguishing the two classification systems, 
Amarenco et al. developed an updated A-S-C-O-D phenotyping of ischemic stroke62. The 
newly evolved form of ASCO added a ‘D’ for dissection, which is frequently identified 
in young stroke patients62. 
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Treatment of Acute Ischemic Stroke 
When an artery within the brain becomes occluded, oxygen and essential nutrients 
are restricted from diffusing to the neuronal cells of the associated vascular territory. The 
cells that suffer irreversible damage comprise the core of the infarct, while the 
surrounding cells that remain metabolically active comprise the area of ischemic 
penumbra63,64. Over time, the area of infarction can expand into the penumbra and 
increase the degree of irreversible cell damage64. The ischemic penumbra is potentially 
salvageable, and therefore, restoration of blood flow to the vascular territory may 
interrupt this expansion63-65. On this basis, interventions for hyperacute stroke patients 
focus on recanalizing the occluded artery, and restoring blood flow to the cells at risk of 
infarction. 
 
Intravenous Fibrinolysis 
For a blood clot to form, there must be some sort of irritating stimuli, which 
triggers the body’s natural response to initiate the blood-clotting cascade. As highlighted 
in Figure 7, this stimulus can be either intrinsic or extrinsic. When tissues are damaged, 
prekallikrein, high-molecular-weight kininogen, and inactive factor XII (Hageman factor) 
form a primary complex on exposed collagen, and activate factor XII, which initiates the 
intrinsic pathway66. On the other hand, when blood vessels are damaged, tissue factor is 
released, leading to the activation of factor VII and the initiation of the extrinsic 
pathway66. These two pathways converge at the activation of factor X, triggering the 
initiation of the common pathway, which involves the enzymatic cleavage of the 
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zymogen precursor, fibrinogen, into the functionally active fibrin. This proteolytic 
cleavage removes two fibrinopeptides, exposing sites on the fibrin molecule, which then 
allows for the molecules to link together66. Stabilized by covalent cross-links between 
glutamine and lysine residues, fibrin molecules begin to form striated fibers, a major 
component of a newly formed blood clot66. 
 
Figure 7: Pathways of Coagulation Cascade67. The intrinsic (upper left) and extrinsic 
(upper right) pathways merge to form the common pathway, which is responsible for the 
conversion of soluble fibrinogen into fibrin. 
 
As damaged tissues and vessels heal, the blood clot must be removed. As 
highlighted in Figure 8, tissue-type plasminogen activator (t-PA) plays an essential role 
in this process by cleaving the proenzyme plasminogen into plasmin, which 
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proteolytically cleaves fibrin into fibrin degradation products and dissolves the clot to 
allow reperfusion of the ischemic tissues66. The utilization of t-PA in the body inhibits 
excessive fibrin production, preventing the formation of unnecessary blood clots. 
Therefore, the concept of enzyme drugs that function to activate the body’s natural 
mechanisms for clot removal began to be explored for clinical applications. 
 
Figure 8: Mechanism of Clot Removal68. The formation of a fibrin clot triggers the 
release of tissue-type plasminogen activator, which proteolytically cleaves plasminogen 
into plasmin. Active plasmin cleaves fibrin into fibrin degradation products. 
 
The use of a recombinant form of human tissue-type plasminogen activator for 
treatment of acute ischemic stroke was supported by two separate clinical trials; the first 
of which was the National Institute of Neurological Disorders and Stroke (NINDS) t-PA 
Stroke Trial (Genentech Protocol A0228s)69. This study was a randomized, placebo-
controlled, double blind trial of intravenous recombinant t-PA (Activase®; alteplase) for 
treatment of patients with ischemic stroke who present within three hours of stroke onset. 
Protocol of the trial consisted of two separate studies that were conducted consecutively 
with identical procedures at the same study sites. Part 1 (291 patients enrolled) assessed 
the clinical benefit of t-PA after 24 hours by evaluating changes in neurologic deficits. 
The National Institutes of Health Stroke Scale (NIHSS), as highlighted in Appendix III, 
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was used for this assessment, where clinical benefit was defined as an improvement of 
four points over baseline NIHSS values, or resolution of the neurologic deficits. Analysis 
of the data revealed no statistically significant difference between patients who were 
given t-PA versus placebo at 24 hours69. 
Part 2 (333 patients enrolled) assessed clinical outcome at 90 days through four 
outcome scales, which included NIHSS, Barthel Index, Modified Rankin Scale (mRS), 
and Glasgow Outcome Scale. The Barthel Index, mRS and Glasgow Outcome Scales are 
highlighted in Appendix IV & V. The criteria for a favorable outcome were: NIHSS = 0-
1, Barthel Index = 95-100, mRS = 0-1, and Glasgow = 1. In comparison to the placebo 
group, the t-PA group demonstrated a 30% higher probability of having minimal or no 
disability at 90 days69. In addition, the mortality rates in the t-PA group and placebo 
group were 17% and 21% (P=0.30), respectively69. While the difference in mortality rates 
were not statistically significant, the reported rates of symptomatic ICH at 36 hours did 
demonstrate statistical significance, with a 6.4% rate in patients given t-PA, and a 0.6% 
rate in patients given placebo (P<0.001)69. 
Simultaneous with the NINDS t-PA Stroke Trial, was the European Cooperative 
Acute Stroke Study (ECASS)70, which was a randomized, placebo-controlled, double 
blind trial that evaluated Actilyse® (alteplase), a different tissue-type plasminogen 
activator, for treatment of patients with acute ischemic stroke who present within six 
hours of symptom onset. The intention-to-treat analysis from the ECASS study (620 
patients enrolled) failed to demonstrate a statistically significant difference between the 
treatment and placebo groups at three months, as assessed by Barthel Index and mRS70. 
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However, after 109 patients were excluded for protocol violations (early infarct signs on 
CT, use of prohibited concomitant therapy, unavailable for follow-up, deviations from 
primary end point assessment), reanalysis of the data revealed a statistically significant 
difference in the mRS, which favored the t-PA treated patients (P=0.035)70. Global end 
point analysis (as used in the NINDS t-PA Stroke Trial) of the data demonstrated an 
increased rate of favorable outcome within the t-PA treatment group (P=0.008)71. The 
ECASS study also demonstrated no statistically significant difference in mortality rate at 
30 days among the t-PA and placebo treated patients. While there were no significant 
differences between the treatment and control groups in regards to the overall incidence 
of ICH, the development of large parenchymal hemorrhages occurred at an 8.8% higher 
rate in the t-PA treatment group (11.1% versus 2.3%)70. While two different methods of 
characterizing ICH were used in the NINDS and ECASS studies, the rates of 
parenchymal hematomas in the ECASS trial were higher than the rates of symptomatic 
hemorrhage reported in the NINDS trial. 
 
Endovascular Intervention 
In addition to standard intravenous t-PA therapy for acute stroke, there are now a 
number of endovascular treatments, including intra-arterial fibrinolysis, mechanical clot 
retrieval, and mechanical clot aspiration. There are a number of mechanical devices that 
have been developed to recanalize occluded vessels, including the Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI) retrieval system (Concentric Medical, Inc.; 
2004), and the Penumbra System (Penumbra, Inc.; 2007). The use of these devices is 
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based on studies without non-interventional control groups, and therefore, without 
randomized comparison, the US Food and Drug Administration (FDA) has no clinical 
indication for their use72. Nevertheless, these devices have been approved by the US FDA 
as mechanical means of recanalization based on their ‘comparability to predicate 
devices’72. 
Evidence for intra-arterial fibrinolysis is primarily based on two randomized 
studies: the Prolyse in Acute Cerebral Thromboembolism (PROACT) II trial73 and the 
Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT)74. Both 
studies focus on the use of urokinase (UK), a serine protease, which is activated by 
fibrin-associated plasmin on the surface of a thrombus74. The primary substrate of UK is 
plasminogen, and once activated, UK readily cleaves the zymogen into plasmin, initiating 
a proteolysis cascade at the site of arterial occlusion73. 
The PROACT II study was a prospective, phase III randomized trial that assessed 
the clinical safety and efficacy of intra-arterial recombinant prourokinase (r-proUK) as a 
treatment for patients with acute ischemic stroke caused by a middle cerebral artery 
(MCA; M1 or M2) occlusion73. In addition, patients needed to present to the hospital 
within six hours from stroke onset to be eligible. A total of 180 patients (121 treated; 59 
control) were enrolled, based on the following criteria: 1) new focal neurological 
symptoms in MCA distribution; 2) NIHSS ≥4, or demonstrate isolated aphasia or 
hemianopia; 3) 18-85 years of age; 4) MCA occlusion proven by angiography, as 
highlighted in Figure 9; 5) lack of hemorrhage or any major early signs of infarction on 
CT. Based on the primary outcome, which assessed degree of neurologic disability at 90 
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days, 25% of patients from the control group, and 40% of patients from the r-proUK 
treatment group had an mRS ≤2 (P=0.04)73. The study also analyzed the secondary 
outcome, which assessed the degree of MCA recanalization, frequency of symptomatic 
ICH, and mortality. MCA recanalization was achieved in 18% of the control group, and 
66% of the r-proUK treatment group (P<0.001)73. On a 24-hour follow-up CT scan, 
symptomatic ICH was observed in 2% of the control group and 10% of the r-proUK 
treatment group (P=0.06)73. Mortality occurred at similar rates between the two groups 
(27% control; 25% r-proUK)73. 
 
Figure 9: Angiography of Right Carotid Artery (frontal view)73. Slide D: Proximal 
M1 occlusion (arrow) confirmed after contrast injection. Slide E: Microcatheter 
(arrowheads) within right internal carotid artery. Slide F: M1 recanalization two hours 
after recombinant prourokinase infusion. 
 
MELT was a randomized study that assessed the clinical safety and efficacy of 
intra-arterial UK in patients with acute ischemic stroke who present within six hours of 
symptom onset74. However, based on the recommendations of Japan’s Independent 
Monitoring Committee, this study was ended prematurely because the use of intravenous 
t-PA was officially approved for treatment of ischemic strokes within 180 minutes of 
symptom onset. When the trial was stopped, a total of 114 patients were enrolled (57 
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each in UK and control group) based on an inclusion and exclusion criteria similar to the 
one used in the PROACT II trial. The UK treatment group demonstrated a higher 
frequency of favorable outcome (primary end point; mRS ≤2) at 90 days, but a 
comparison with the control group did not reach statistical significance (49.1% UK; 
38.6% control; P=0.345)74. However, an evaluation of excellent functional outcome 
(secondary end point; mRS ≤1) at 90 days showed a statistically significant difference 
between the treatment and control group (42.1% UK; 22.8% control; P=0.045)74. In 
addition, a significantly higher amount of patients from the UK group had an NIHSS ≤1 
at 90 days (P=0.017)74. The mortality rates at 90 days for the UK group and control group 
were 5.3% and 3.5% (P=1.000), respectively74. At 24 hours, symptomatic ICH was 
observed in 9% of treated cases and 2% of control cases (P=0.206)74. The treatment effect 
and rate of symptomatic ICH were consistent with the results from the PROACT II trial. 
A meta-analysis of these two studies demonstrated evidence in support of the intra-
arterial fibrinolytic treatment approach75,76. 
In acute ischemic stroke, mechanical thrombectomy is considered both a primary 
reperfusion strategy, as well as a combination therapy with pharmacological 
fibrinolysis77. The US FDA has currently approved four devices for use in recanalizing an 
arterial occlusion, but only the first two devices to receive clearance will be discussed 
because these systems opened the market to mechanical thrombectomy. The first 
approved device was the MERCI Retrieval System in 2004. As seen in Figure 10, the 
basis of this device involves a series of helical loops, which deploy from a microcatheter 
to engage and capture the clot72. In the MERCI trial, a prospective, multicenter study, the 
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MERCI Retriever was evaluated in ischemic stroke patients who were ineligible for 
intravenous t-PA, but demonstrated the presence of an arterial occlusion and presented to 
the hospital within eight hours from symptom onset78. The MERCI device was used in 
141 patients, of which 48% (n=68) recanalized78. This rate of recanalization is 
significantly higher than the benchmark of spontaneous recanalization at 18% 
(P<0.0001)78, which was demonstrated two hours after angiography in the control group 
of the PROACT II trial73. Clinically significant complications, including ICH with 
neurological deterioration, were observed in 7.8% (n=11) of patients78. At 90 days, 
patients who successfully recanalized were compared with patients who unsuccessfully 
recanalized for good neurological outcome (mRS ≤2), which occurred at a rate of 46% 
and 10% (P<0.0001), respectively78. In addition, mortality within these groups was 
observed in 32% and 54% (P=0.01), respectively78. The investigators concluded that this 
novel endovascular device was efficient at restoring blood flow to an occluded artery, 
particularly in patients who are otherwise ineligible for thrombolytics. 
 
Figure 10: MERCI Retrieval System79. The corkscrew-shaped retriever is deployed 
from the microcatheter to engage the thrombus. As the retriever is retracted, the thrombus 
is removed from the artery, allowing for a restoration of blood flow. 
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The second device to receive US FDA clearance was the Penumbra System in 
2007. As seen in Figure 11, the basis of this device involves a pump, which generates a 
vacuum to aspirate the thrombus via a catheter72. In the pivotal Penumbra trial, a 
prospective, multicenter study, the Penumbra System was evaluated in 125 patients with 
an NIHSS ≥8, an angiographic occlusion, and presented within eight hours from the onset 
of symptoms80. Patients who presented within three hours needed to be either ineligible or 
refractory to intravenous t-PA. Results from the MERCI trial were used as the historical 
control. The Penumbra System either partially or completely recanalized 81.6% of treated 
vessels80. Procedural complications and symptomatic ICH was reported in 12.8% and 
11.2% of cases, respectively80. Overall, 25% of treated patients demonstrated a good 
clinical outcome (mRS ≤2) at 90 days, while 32.8% of treated patients died80. 
The results from the Penumbra trial were supported by a retrospective, 
multicenter case review, which evaluated 157 patients who were treated with the 
Penumbra System81.  Within this case review, 87% of treated patients demonstrated either 
partial or complete vessel recanalization81. Procedural complications and symptomatic 
ICH (defined by evidence of ICH within 24 hours on CT and clinical deterioration of 
NIHSS >4 points) occurred in 5.7% and 6.4% of cases, respectively81. At 90 days, 41% of 
patients demonstrated a good functional outcome (mRS ≤2), while 20% died81. These 
investigators concluded that the Penumbra endovascular device is safe and effective at 
removing a large vessel occlusion, particularly in patients ineligible or refractory to 
intravenous t-PA. 
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Figure 11:Penumbra System82. Slides 4 & 5 demonstrate how the separator within the 
reperfusion catheter penetrates a thrombus and then breaks it into pieces. Slide 6 
demonstrates how the reperfusion catheter utilizes a vacuum to aspirate the clot pieces. 
 
US Food and Drug Administration Guidelines for use of Alteplase 
With the completion of the small, pilot study (#87-906), “Protocol for the 
Evaluation of Tissue Plasminogen Activator Early in the Course of Acute Stroke”83, 
multiple dose-escalation studies83-85, NINDS t-PA Stroke Trial69, and ECASS trial70, the 
US FDA had enough supportive evidence to approve the use of intravenous recombinant 
t-PA to treat patients with acute ischemic stroke. In 1996, this approval by the US FDA 
became official, with a specific set of eligibility criteria, as highlighted in Appendix VI. 
The eligibility criteria released by the US FDA did not stray from the criteria used in the 
NINDS t-PA Stroke Trial. To be eligible, patients needed to be at least 18 years old, have 
a disabling neurologic deficit, and receive treatment within 3 hours of stroke onset. 
Patients were ineligible for treatment if they were currently taking anticoagulants, or had 
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a history of ICH, recent stroke, or recent head trauma. In addition, patients were deemed 
ineligible if they recently underwent major surgery, or recently had an active internal 
hemorrhage. As part of the clinical assessment, diagnostic tests were used to confirm: a 
blood pressure below 185/110 mmHg; a glucose concentration between 50-400 mg/dL 
(2.7-22.2 mmol/L); a normal partial-thromboplastin time; an international normalized 
ration (INR) below 1.7; a prothrombin time less than 15 seconds; and a platelet count 
above 100,000/mm3. For neuroimaging, a baseline CT scan was required to rule out acute 
ICH or SAH. 
 
American Heart & Stroke Association Guidelines for Intravenous Fibrinolysis 
 Since its approval in 1996, intravenous recombinant t-PA has been extensively 
studied, and is now a widely accepted therapy for acute ischemic stroke86-94. In 2013, with 
additional clinical data and advancements in technology, the American Heart Association 
Stroke Council published “Guidelines for the Early Management of Patients with Acute 
Ischemic Stroke”72. Within these guidelines is a modified version of the US FDA’s 
eligibility criteria for the use of intravenous fibrinolysis within three hours of stroke 
onset, as highlighted in Appendix VII. While there were no modifications to the inclusion 
criteria, the exclusion criteria now include intracranial neoplasms, AVMs, and 
aneurysms. In addition, a patient is ineligible for treatment if the baseline CT scan 
demonstrates a multilobar infarction, where at least a third of the cerebral hemisphere is 
involved. The most significant modification incorporates the addition of relative 
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exclusion criteria, which involves weighing the risk to benefit ratio of administering 
intravenous t-PA against relative contraindications. The relative exclusion criteria 
incorporate pregnancies, seizures at onset, major surgeries, serious traumas, abdominal 
hemorrhages, and myocardial infarctions. 
 
Imaging of Acute Ischemic Stroke 
Intravenous administration of recombinant t-PA remains the only US FDA 
approved pharmacological therapy for patients with acute ischemic stroke95. However, 
the use of intravenous t-PA is associated with an increased rate of ICH, which may be 
fatal. Therefore, the best method of reducing the risk of ICH is through proper 
identification and careful selection of patients who will benefit the most from fibrinolytic 
therapy. A necessary component of the emergent assessment of patients suspected of a 
stroke or TIA is brain and vascular imaging, which can determine the size and location of 
infarction, as well as the vascular distribution. In addition, imaging modalities can detect 
the severity of ischemic stroke, and presence of hemorrhage or large-vessel occlusion, 
which assists with both short- and long-term treatment decisions72. Advancements in 
brain imaging techniques can now capture the status of intracranial vessels, the current 
hemodynamic status, as well as help predict the reversibility of ischemic injury96,97. The 
two types of non-invasive brain and vascular imaging modalities commonly used in the 
assessment of hyperacute ischemic stroke include computed tomography and magnetic 
resonance imaging. 
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Computed Tomography 
Computed tomography is an imaging technique that involves generating images 
of a plane. As seen in Figure 12, an x-ray source rotates circumferentially around the 
body of a patient and produces a narrow, fan-shaped beam, which can range from 1 
millimeter (mm) to 10 mm98. The detectors record the x-rays that exit the patient’s body, 
and send this information to a computer, which utilizes a back-projection technique, 
based on attenuation characteristics, to reconstruct a two-dimensional image of the 
tissues99. The density of the scanned tissue determines these attenuation characteristics, 
where bone and other dense tissues appear bright, while less dense tissues appear darker. 
It should be noted that although bone can be easily visualized on CT, it has tendency to 
produce artifact at the bone and soft tissue interfaces98,99. 
  
Figure 12: Computed Tomography98. The image on the left shows a patient entering 
the circular opening of a CT imaging system. The image on the right demonstrates the x-
ray source and detectors rotating circumferentially around a patient. 
 
During a CT scan, the narrow x-ray beams pass through a patient and interact 
with the individual atoms, specifically the clouds of electrons that orbit the nuclei, which 
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comprise the human body100. The sensors then detect the varying amounts of 
electromagnetic radiation that exit the patient’s body, which is dependent on the density 
of the scanned tissue. More specifically, the type of medium that the x-rays pass through 
determines the attenuation characteristics. For example, air and fat are readily identified 
on a CT scan because of their characteristically low attenuation99. Another component 
encountered in neuroimaging is CSF, which has an attenuation similar to water. The CSF 
is less dense than the surrounding gray and white matter of the brain, and therefore, 
appears darker. As for distinguishing the gray and white matter, the difference in 
densities is usually sufficient in separating the two neural tissues. In assessing a stroke 
patient, an important distinction involves the contrasting attenuation characteristics of 
normally flowing blood and brain tissue, where blood is denser, and therefore, appears 
brighter. This is also true in an acute hematoma, which is even denser than flowing blood 
because of clot retraction and the loss of water99. 
CT can often detect pathological processes in the brain due to the presence of 
edema, or swelling caused by an abnormal accumulation of fluid, which is less dense than 
normal neural tissue99. In addition, CT can detect increased densities within lesions, 
which can occur in a number of conditions, such as within tumors with a high nuclear-to-
cytoplasmic ratio. CT can also readily detect calcifications, which are denser than the 
surrounding brain tissue, and therefore, appear brighter99. When an iodinated contrast is 
injected intravenously, enhancement (high density) can occur in the presence of increased 
vascularity and/or when there is a breakdown of the blood-brain barrier99. 
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Magnetic Resonance Imaging 
Magnetic resonance imaging is a technique that also generates images of a cross-
sectional plane. However, the physical basis of how these images are acquired is 
completely different from CT. While CT imaging relies on the interaction between x-rays 
and orbiting electrons, MRI relies on presence of water, which makes up 70-90% of most 
tissues100. The foundation of MRI is based on the physical properties of water, 
specifically the magnetic properties of the hydrogen proton. The hydrogen protons of a 
water molecule have a tendency to align with a very strong, external magnetic field. 
Therefore, when a patient enters an MRI scanner, these hydrogen protons will magnetize 
and align with the magnetic field produced by the scanner, which is typically denoted as 
the z or longitudinal axis. The strength of magnetization is dependent on the proton 
density (PD) within a given tissue, which can dramatically change with disease or 
injury100.  
To produce MR images, the magnetization of the hydrogen atoms must be 
knocked out of alignment. To do this, a short-term radiofrequency (RF) pulse is applied 
(x-y or transverse axis), specifically one that matches the magnetic resonance of the 
hydrogen protons, and these protons magnetize in the direction of the pulse100, as 
highlighted in Figure 13. The net result is hydrogen protons that are briefly in phase with 
each other, which produces a weak, but detectable electromagnetic signal99. Specialized 
coils (antennas) that surround the patient within the bore of the MRI scanner detect these 
weak electromagnetic signals. Acquisition of these signals is dependent on the signal 
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intensity, which is determined by the relaxation properties of the tissue, PD, and gross 
moment of hydrogen protons, especially within moving blood and CSF99. 
Once the external RF pulse, which has a highly controlled timing, is terminated, 
the electromagnetic signal produced by the aligned hydrogen atoms begins to fade. The 
signal fades as a result of the hydrogen protons returning to an alignment that matches the 
initial, external magnetic field generated by the scanner, a process known as spin-lattice 
relaxation. In addition, the signal fades as nearby molecules interact and disrupt phase 
coherence, a process known as spin-spin relaxation99,100. As highlighted in Figure 13, 
spin-lattice relaxation determines the growth and recovery rate of magnetization along 
the z-axis, while spin-spin relaxation determines the rate of decay along the transverse 
axis100. Both of these processes are based on exponential decay kinetics99. 
Both spin-lattice and spin-spin relaxations have a characteristic time constant, 
known as spin-lattice relaxation time (T1) and spin-spin relaxation time (T2). T1 controls 
the magnetic recovery, while T2 controls the magnetic decay. In the human body, tissues 
have varying compositions, and therefore, different T1 and T2 properties. Fluids typically 
have long T1s (1500-2000 milliseconds (ms)) and the longest T2s (700-1200 ms)100. 
Water-based tissues typically make up the mid-range in terms of T1 and T2 (400-1200 ms 
and 40-200 ms, respectively), while fat-based tissues typically have short T1s and T2s 
(100-150 ms and 10-100 ms, respectively)100. In a given tissue, T1 and T2 are independent 
of each other, and T1s are always longer than T2s100. 
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Figure 13: The Basis of Magnetic Resonance Imaging100. (a) Vectors of the hydrogen 
atoms (blue & black vectors represent two different tissues with different PD) align with 
the external magnetic field generated by the MRI scanner. (b) When an RF pulse is 
applied, the alignment vectors change, creating an electromagnetic signal. (c-e) Period of 
relaxation, with T2 controlling decay in the y-axis and T1 controlling recovery in the z-
axis. The black vector has a much longer T2 and T1 than the blue vector. (f) Hydrogen 
atoms within the two different tissues relax and return to initial alignment. 
 
Generating signal contrast is dependent on three essential properties of human 
tissues, specifically PD, T1 and T2. All three of these properties contribute to the intensity 
of an image, but the degree of contribution each makes is dependent on the manipulation 
of the repetition time (TR) and the echo time (TE) of the sequence. The TR is the amount 
of time between successive RF pulses, while the TE is the time from the pulse to the 
echo, which is the signal as it returns from the patient100. T1-weighted images (T1WIs) are 
predominantly based on the T1 properties of the scanned tissue, and utilize a short TR and 
TE99. On the other hand, T2-weighted images (T2WIs) are predominantly based on the T2 
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properties of the scanned tissue, and utilize a long TR and TE99. Additional sets of images 
with intermediate characteristics, known as PD-weighted images, depend on the PD of 
the scanned tissue, and utilize a long TR and short TE99. 
The two most common sequences utilized in MRI are spin-echo (SE) and 
gradient-echo (GE). Both of these sequences can be manipulated to generate T1WIs, 
T2WIs, or PD-weighted images. SE sequences are based on the use of a 90° RF pulse, 
and varying TR and TE values. As seen in Table 1, SE T1WIs are produced with a short 
TE (<40 ms) and a short TR (<750 ms), while T2WIs are produced with a long TE 
(>75ms) and a long TR (>1500 ms)100. SE PD-weighted images are generated with a short 
TE (<40 ms) and a long TR (>1500 ms), while sequences that utilize a long TE (>75 ms) 
and a short TR (<750 ms) generate images that are not useful100. While SE sequences 
involve the manipulation of TE and TR to generate the images, GE sequences instead 
involve the manipulation of TE and flip angle α, which is an RF pulse less than 90°99. For 
GE sequences, the TR used is always shorter (<750 ms) that the TR used in SE 
sequences. As seen in Table 2, GE T1WIs are produced with a short TE (<15 ms) and a 
large flip angle α (>50°), while T2WIs are produced with a long TE (>30 ms) and small 
flip angle α (<40°)100. GE PD-weighted images are generated with a short TE (<15 ms) 
and a small flip angle α (<40°), while sequences that utilize a long TE (>30 ms) and a 
large flip angle α (>50°) generate images that are not useful100. Since GE sequences 
utilize shorter TE and TR values than SE sequences, the scan duration for GE sequences 
is much shorter, which allows for more rapid image acquisition. 
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Table 1: Spin-Echo Sequences100 
Repetition Time (TR) Echo Time (TE) 
Short (<40 ms) Long (>75 ms) 
Short (<750 ms) T1-weighted Not useful 
Long (>1500 ms) PD-weighted T2-weighted 
 
Table 2: Gradient-Echo Sequences100 
Flip angle α Echo Time (TE) 
Short (<15 ms) Long (>30 ms) 
Small (<40°) PD-weighted T2-weighted 
Large (>50°) T1-weighted Not useful 
 
As indicated above, either SE or GE sequences can produce T1-weighted images, 
as long as the TE and TR are short during image acquisition. When utilizing SE 
sequences, T1WIs demonstrate excellent contrast between various tissues: fluids 
appearing very dark (unless fast moving), water-based tissues appearing mid-gray, and 
fat-based tissues appearing very bright100. In addition, white matter appears brighter than 
gray matter in the brain. In assessing tissue pathology, anything that changes the T1 
properties of the scanned tissue, alters its appearance on a T1WI. For example, the 
presence of edema or an excessive amount of capillaries will result in a tissue appearing 
darker than the surrounding, normal tissue. When utilizing GE sequences, the tissues 
within the T1WIs have a similar contrast scheme to SE images, but GE images are 
acquired much more rapidly; GE images also demonstrate an excellent signal-to-noise 
ratio and a high degree of resolution100. 
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Both SE and GE sequences can also produce T2-weighted images, as long as the 
TE is long during image acquisition. When utilizing SE sequences, T2WIs also 
demonstrate excellent contrast between various tissues: fluids appearing very bright, and 
water-based and fat-based tissues appearing mid-gray. T2 images are often used to 
determine pathology, because the accumulation of abnormal fluids appears bright in 
contrast to the darker normal tissue100. When utilizing GE sequences, the tissues within 
the T2WIs have the same basic contrast scheme as in SE images, despite the presence of 
inhomogeneities in the magnetic field. These inhomogeneities, caused by susceptibility 
effects, such as air pockets, dense bone, and blood breakdown products found in the 
scanned tissues, result in an imperfect magnetic field. The lack of a perfect magnetic field 
alters the relaxation of tissues following an RF pulse, which speeds up the apparent spin-
spin relaxation time constant, known as T2*. However, the imaging contrast remains 
similar because T2* is closely related to T2100. These inhomogeneities only impact GE 
sequences, as SE sequences can correct for this effect. For a summary on how different 
tissues and mediums appear on different MRI sequences, see Table 3. 
An intravenous, gadolinium-based contrast agent can be used during various MRI 
sequences to enhance specificity. Gadolinium is a metallic element with paramagnetic 
qualities, which impacts tissues by shortening T1 and enhancing the image signal99. The 
use of gadolinium is particularly useful in identifying highly vascular tumors, or when the 
blood-brain barrier is disrupted100. In both cases, gadolinium accumulates in the diseased 
or damaged tissue, increasing the signal on T1WIs99,100. 
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Table 3: Tissue & Medium Characteristics on MRI 
Tissue/Medium Spin-Echo (SE) Gradient-Echo (GE) 
T1 T2 T1 T2 
Air Dark Dark Dark Dark 
Bone Dark Dark Dark Dark 
Calcium (dense) Dark Dark Dark Dark 
Calcium (non-dense) Bright  – Bright – 
Cerebrospinal Fluid Dark Bright Dark Bright 
Deoxyhemoglobin – Dark – Dark 
Fat Bright Dark Bright Dark 
Flowing blood Dark Dark Bright Bright 
Gadolinium contrast Bright – Bright – 
Hemosiderin – Dark – Dark 
Methemoglobin Bright – Bright – 
Methemoglobin 
(intracellular) – Dark – Dark 
Methemoglobin 
(extracellular) – Bright – Bright 
Water Dark Gray Bright Dark Gray Bright 
White & Gray Matter* WM > GM GM > WM WM > GM GM > WM 
* In comparing white & gray matter, > indicates which is brighter 
 
American Heart & Stroke Association Guidelines for Imaging Acute Stroke 
In January 2013, the American Heart Association (AHA) Stroke Council 
published, “Guidelines for the Early Management of Patients with Acute Ischemic 
Stroke”72. As highlighted in Appendix VIII, this publication included recommendations 
for imaging of acute ischemic stroke, particularly for patients with unresolved symptoms. 
Despite the significant advancements in CT and MRI technology, the AHA Stroke 
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Council recommends that in most cases, non-contrast-enhanced computed tomography 
(NECT) will provide sufficient information to make critical, emergent medical decisions. 
In addition, the AHA Stroke Council recommends that either NECT or MRI be 
performed before intravenous t-PA administration to rule out acute hemorrhage. If acute 
endovascular therapy is being considered, the AHA Stroke Council strongly recommends 
intracranial vascular imaging. 
The goal of this thesis is to evaluate both CT and MRI imaging modalities in the 
setting of acute ischemic stroke. A thorough comparison of current CT and MRI 
technologies will reveal that NECT is not only an inadequate means of imaging acute 
ischemic stroke, but that MRI is the superior imaging method. This distinction is 
necessary in order to potentially influence current clinical guidelines, like those released 
by the AHA Stroke Council, and initiate a change in the urgent evaluation of stroke 
patients across all clinical stroke centers. This change will not only assist stroke 
physicians in making better treatment decisions, but will also benefit the patients by 
reducing the risk of hemorrhage. The combination of improving the diagnosis and 
treatment of cerebrovascular disease will ultimately minimize stroke-related costs in the 
future. For anatomical reference between these two imaging modalities, see Appendix 
IX-XI. 
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PUBLISHED STUDIES 
 
When assessing a patient for intravenous t-PA therapy, the most important aspect 
of imaging acute ischemic stroke is ruling out hemorrhage, which is an absolute 
contraindication. However, with the emergence of new technologies, imaging should now 
be used to assess whether a patient has an intravascular thrombus that can be treated with 
thrombolysis, thrombectomy, or a combination therapy. The premise behind utilizing 
imaging to detect the presence of an intravascular thrombus is to improve the efficacy of 
treatment. For example, randomized, controlled studies have demonstrated that 
intravenous t-PA is most effective in small-vessel occlusions101. In addition, imaging 
should be used to determine the presence and size of the core of irreversibly infarcted 
tissue, as well as identify hypoperfused tissue at risk of infarction. Imaging can also play 
a vital role in identifying and excluding patients based on stroke mimics, or due to the 
presence of factors that increase the likelihood of ICH. Overall, neuroimaging should be 
used to help identify and select patients who will benefit the most from fibrinolytic 
therapy, as well as to help exclude patients with a higher risk of bleeding. 
 
Imaging of Cerebral Parenchyma 
Non-contrast-enhanced computed tomography still remains the most common 
modality of imaging patients suspected of TIA and acute ischemic stroke. NECT has 
definitively demonstrated the ability to detect large parenchymal hemorrhages102,103. The 
high attenuation of blood leads to a hyperdense lesion, as highlighted in Figure 14. Due 
	  36	  	  
to this easily identified characteristic, NECT served as the primary imaging modality in 
the evaluation of potential intravenous t-PA treatment cases in the NINDS69 and ECASS70 
stroke trials, but these studies did not evaluate the accuracy of utilizing NECT in the 
detection of ICH. NECT, however, has demonstrated a high specificity in detecting even 
small amounts of SAH104-107, which is also essential in the acute evaluation of stroke 
patients. 
Magnetic resonance imaging can also readily detect parenchymal hemorrhage, but 
this is dependent on which sequence is used, as well as the age of the blood108-111. T2*-
weighted sequences can detect even small hemorrhages due to the presence of 
deoxyhemoglobin, or other paramagnetic compounds that contain iron or calcium72. The 
presence of deoxyhemoglobin in a T2*-weighted sequence causes heterogeneous signal 
intensity, resulting in tissue that appears darker than the surrounding normal tissue, as 
seen in Figure 14. Two prospective studies that evaluated stroke patients who presented 
within 6 hours from symptom onset, determined that MRI and CT are equivalent at 
detecting hyperacute ICH108,112. In one of these studies, Kidwell et al. specifically 
compared CT and gradient recalled echo (GRE) MRI in the detection of acute ICH (200 
patients), and determined that there was a 96% concordance between the two imaging 
modalities108. Kidwell et al. also discovered that in four cases of hemorrhagic 
transformation in areas of ischemia, MRI detected acute hemorrhage, while CT did not108. 
In addition, small, chronic hemorrhages, known as microbleeds, were detected in 49 
patients with MRI, but were not visualized on CT, as highlighted in Figure 15. In terms 
of detecting SAH, T2 fluid-attenuated inversion recovery (FLAIR) sequences can detect 
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small amounts of blood within the subarachnoid space113. In conclusion, MRI is just as 
effective as NECT at detecting acute hemorrhage, and therefore, could be used as an 
initial imaging technique for evaluating potential stroke patients for fibrinolytic therapy. 
 
Figure 14: Acute Hemorrhage on CT and MRI108. A) CT scan demonstrates acute 
hemorrhage (1 hour & 54 minutes from onset), as highlighted by the hyperdense lesion 
(white arrowhead). B) MRI GRE scan demonstrates acute hemorrhage (1 hour & 12 
minutes from onset), as highlighted by the darker neural tissue (black arrowhead). 
 
 
Figure 15: Chronic Microbleeds on CT and MRI108. Gradient recalled echo MRI 
sequences demonstrate the presence of small, chronic hemorrhages, known as 
microbleeds (black arrowheads), while CT does not. 
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Non-contrast-enhanced computed tomography also has the ability to detect early 
cerebral ischemia. Within the first few hours of a stroke, neural tissue is damaged, thus 
resulting in the accumulation of water and the loss of differentiation between gray and 
white matter114-116. As highlighted in Figure 16, the subtle indications of parenchymal 
damage, such as blending of neural tissue densities, swelling of the gyri, and ventricular 
compression, can appear within 3 hours from symptom onset117-119. The sooner these 
parenchymal indications become evident, the more severe the cerebral ischemia. 
However, the observers’ ability to detect these early signs on NECT is highly inconsistent 
due to the variability of infarct severity, size and location, and the duration of time 
between imaging and stroke onset120,121. Reportedly, the early signs of infarction are 
detectable in ≤67% of patients who present to the hospital within 3 hours from symptom 
onset72. In addition, NECT is relatively insensitive in detecting acute, small cortical and 
subcortical infarctions, as well as ischemia in the posterior fossa122. In a post hoc analysis 
of the NINDS t-PA Stroke Study, Patel et al.119 reported a 31% sensitivity for the 
detection of early infarct signs on NECT; this sensitivity increases to 82% after six hours 
from stroke onset, but by this point, the patient is outside of the t-PA treatment 
window123. Improved CT windowing and leveling124, as well as the use of the Alberta 
Stroke Program Early CT Score (ASPECTS)120,121 may increase the likelihood of 
detecting the early signs of infarction. 
Another significant, early, sign on CT is the detection of an increased density 
within the occluded artery, known as the hyperdense vessel sign. As highlighted in Figure 
18, a hyperdensity within a middle cerebral artery (hyperdense MCA sign) is indicative 
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of a large-artery occlusion125. However, the hyperdense MCA sign is seen in only 33-50% 
of cases with an angiographically proven thrombus126,127. Therefore, the presence of a 
hyperdense vessel sign is an appropriate indicator of a thrombus, but the lack of a 
hyperdense vessel sign does not rule out an occlusion. In addition, NECT can also detect 
a hyperdense MCA “dot” sign, which is indicative of a more distal MCA occlusion128. 
The presence of a hyperdense MCA “dot” sign is significant because more distal clots are 
typically more receptive to intravenous t-PA101. Barber et al. reported that patients with a 
hyperdense MCA “dot” sign demonstrated a better functional outcome than patients 
without the MCA “dot” sign128. However, after an angiographic evaluation, the MCA 
“dot” sign only demonstrated 38% sensitivity, but 100% specificity129. In addition, it is 
important to note that such hyperdense vessel signs can also be detected in the basilar 
artery130,131. 
Magnetic resonance imaging, specifically T2 diffusion-weighted imaging (DWI), 
is highly sensitive to the neural changes associated with acute ischemia. During an 
ischemic event, neural cells begin to swell (cytotoxic edema), which restricts the ability 
of water molecules to diffuse. As highlighted by Figure 16, restricted diffusion results in 
a hyperintensity on DWI, with a correlating hypointensity on apparent diffusion 
coefficient (ADC) sequences100. In detecting acute ischemia, DWI has demonstrated 88-
100% sensitivity and 95-100% specificity132-134, while CT has demonstrated 61% 
sensitivity and 65% specificity134. DWI has also demonstrated the ability to detect acute 
ischemia within minutes of stroke onset132,135-137. In addition, while CT is relatively 
insensitive to small cortical and subcortical lesions, DWI is highly sensitive in detecting 
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these lesions. DWI can also detect ischemic lesions in the brain stem and cerebellum, 
which are poorly visualized on NECT138-140. Findings on DWI not only provide official 
proof of a stroke or TIA, but also demonstrate the specific size and location of infarction. 
More importantly, subsequent DWI sequences can provide an indication of rare tissue 
recovery, as indicated by either partial or complete reversal of DWI abnormalities141,142. 
 
Figure 16: Acute Ischemia on MR DWI & CT132. The top row demonstrates a right 
MCA infarction, as indicated by the hyperintense region of ischemia on DWI (2 hours & 
15 minutes from stroke onset). The bottom row demonstrates a subtle, corresponding loss 
of definition in the putamen and caudate on NECT (arrows; 2 hours & 45 minutes from 
stroke onset). 
 
Magnetic resonance imaging can not only identify the size and location of an 
ischemic lesion, but certain sequences can also help determine the relative age of the 
infarction. Following an ischemic event, signal intensity on FLAIR sequences increase 
over time, and therefore, these images provide a “tissue clock” to help determine whether 
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a patient should receive intravenous thrombolytics143,144. In 120 patients, Thomalla et al.143 
reported a DWI-positive and FLAIR-negative correlation among patients who presented 
within three hours from symptom onset, as highlighted by Figure 17. This correlation was 
reported with 93% specificity, 48% sensitivity, 94% positive predictive value, and 43% 
negative predictive value143. Thomalla et al. concluded that a mismatch between positive 
DWI and negative FLAIR could be used to help identify eligible patients for 
thrombolytics143. These findings were supported by Ebinger et al.144, who reported a mean 
time of onset in FLAIR-positive patients of 189 minutes (interquartile range 110-369 
minutes) and a mean time of onset in FLAIR-negative patients of 103 minutes 
(interquartile range 75-183 minutes; P=0.011). Within 4.5 hours from symptom onset, 
FLAIR-negative sequences demonstrated 46% sensitivity and 79% specificity in 
treatment-eligible patients144. 
 
Figure 17: MR DWI & FLAIR Sequences at Multiple Time Points144. At 3, 9.5, and 
12 hours from symptom onset, a DWI-positive lesion is present, while a FLAIR-positive 
lesion is only present after 3 hours. 
	  42	  	  
A large-vessel occlusion can also be visualized on a T2*-weighted MR sequence. 
As highlighted in Figure 18, MR sequences demonstrate an artery susceptibility sign, 
which correlates with the hyperdense vessel sign on NECT. In a study that compared CT 
and MRI in evaluating proximal MCA occlusions, Flacke et al.127 reported 54% 
sensitivity in detecting hyperdense MCA sign on CT, and 82% sensitivity in detecting 
MCA susceptibility sign on MR GRE. In addition, GRE sequences are more effective at 
demonstrating the presence of distal clots145. FLAIR sequences can also detect an 
intravascular occlusion, as determined by the presence of a hyperintense vessel. In a 
comparative study, Assouline et al.146 reported the presence of a GRE vascular 
susceptibility sign in 88% of patients, while 100% of patients demonstrated the presence 
of a hyperintense vessel on FLAIR sequences. Both MR GRE and FLAIR were more 
effective than NECT (60% of patients) at demonstrating the presence of an occlusion146. 
Thrombus characterization has proved difficult in both NECT and MRI due to the small 
size of clots147. 
 
Figure 18: Hyperdense & Susceptibility MCA Sign127: a.) CT scan demonstrating the 
presence of a hyperdense MCA sign of the left MCA (white arrows). b.) T2* -weighted 
MR sequence demonstrating an MCA susceptibility sign of the left MCA (black arrows). 
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Imaging of Intracranial Vasculature 
In the emergent assessment of patients with stroke or TIA, it is important to image 
the intracranial vasculature. Helical CT angiography (CTA), which utilizes iodinated 
contrast, is a rapid and noninvasive means of evaluating intracranial vessels for the 
presence of an occlusion or stenosis148,149. Recent advancements in CTA technology, 
particularly the use of more detectors, have increased the spatial resolution to twice that 
of MR angiography (MRA)150. Therefore, CTA has demonstrated high accuracy, 
specifically 92-100% sensitivity and 82-100% specificity (91-100% positive predictive 
value), in detecting large-artery intracranial occlusions and stenoses148,151-153. However, it 
should be noted that the published sensitivities and specificities in detecting intracranial 
stenoses are slightly lower than those reported for intracranial occlusions148,151,153,154. In 
addition, the ability of CTA to detect intracranial occlusions and stenoses decreases in 
more distal vessels155. Despite this limitation, CTA is viewed as a safe and accurate 
method of imaging most intracranial vessels. 
Intracranial CTA source images (CTA-SI), which reflect cerebral blood volume, 
can also be used to detect ischemic regions. In comparison with MR DWI sequences, 
CTA-SIs have demonstrated a high degree of similarity between the sensitivities of the 
two imaging techniques. However, DWI still remains the most effective imaging 
modality in detecting smaller ischemic lesions, especially within the brainstem and 
posterior fossa156,157. When compared with NECT, CTA-SI is much more accurate in 
demonstrating localization of infarction and occluded vessel(s)158, as well as identifying 
tissue that will ultimately become infarcted159,160. 
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MR angiography, as demonstrated in Figure 19, is commonly combined with 
brain MRI in the assessment of acute stroke in order to assist with therapeutic decision-
making. MRA options include 2-dimensional time-of-flight (TOF), 3-dimensional TOF, 
multiple overlapping thin-slab acquisition, and contrast-enhanced MRA (CE-MRA)161. 
Intracranial non-enhanced TOF techniques have demonstrated 60-85% sensitivity in 
detecting stenoses, and 80-90% sensitivity in detecting occlusions153,154. While TOF 
techniques can reliably identify proximal large-artery occlusions, they are unable to 
consistently identify more distal occlusions162. CE-MRA, which utilizes gadolinium 
contrast, provides more accurate imaging than non-enhanced TOF techniques, and 
therefore, CE-MRA is performed on a more routine basis in the setting of acute ischemic 
stroke163,164. Both MRA and CTA techniques generate static images of vascular anatomy, 
and therefore, do not provide information on the current hemodynamic status165. 
  
Figure 19: Contrast-enhanced CTA166 & Time-of-flight MRA167. The image on the left 
demonstrates intracranial vessels (decreased left MCA enhancement) on contrast-
enhanced CTA. The image on the right demonstrates intracranial vessels on TOF MRA. 
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Imaging of Cerebral Perfusion 
Surrounding the core of infarction is the ischemic penumbra, which is comprised 
of neural cells that remain metabolically active in the presence of hypoperfusion63,64. This 
ischemic penumbra is potentially salvageable, and therefore, it is essential that blood flow 
be restored to the vascular territory in the hope of preventing expansion of the ischemic 
core63-65. However, parenchymal and vascular imaging sequences cannot generate images 
that identify tissues at risk of infarction. In order to visualize the ischemic penumbra and 
regional cerebral hemodynamics, brain perfusion imaging techniques are required. A 
combination of parenchymal and perfusion imaging allows for delineation of the 
ischemic core and penumbra168-171. Visualization of the ischemic penumbra allows for the 
proper identification and selection of patient populations who will benefit the most from 
treatment. In addition, visualization of the ischemic penumbra can assist with 
determining which treatment option would best recanalize the occluded vessel. 
Computed tomography perfusion (CTP) and magnetic resonance perfusion (MRP) 
both utilize an injectable contrast agent, specifically a non-diffusible tracer. Assuming 
there is no break in the blood-brain barrier, this tracer should remain in the vasculature. 
CTP sequences, based on cine acquisition, measure the iodinated contrast agent during 
the first pass and generate quantitative cerebral blood flow (CBF; CBF=CBV/MTT), 
cerebral blood volume (CBV), and mean transit time (MTT) maps165. As highlighted in 
Figure 20, penumbra is identified as the area of MTT-CBV mismatch, or CBF-CBV 
mismatch172,173. In comparison to MRP, CTP is more readily quantified because of better 
spatial resolution and a linear relationship between iodinated contrast concentration and 
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resulting image density; such a relationship does not hold between MRP gadolinium 
contrast concentration and resulting signal intensity. In addition, CTP is less sensitive to 
contrast contamination associated with large vascular structures. Therefore, CTP is 
viewed as more reliable than MRP in the assessment of core-penumbra mismatch174,175.  
 
Figure 20: Ischemic Penumbra by Computed Tomography Perfusion172. Patient 
imaged at 2.3 hours and 3 days. A) CBV with infarct core highlighted by red outline 
(arrow). B) CBF with penumbra highlighted by yellow outline. C) Follow-up NECT with 
final infarct core highlighted by blue outline. D) CBF with the red region highlighting 
original infarct core, the blue region highlighting area of penumbra that infarcted, and the 
green region highlighting area of penumbra that recovered. 
 
In comparison with NECT and CTA-SI, CTP source images have demonstrated a 
higher accuracy at identifying regions of reversible and irreversible ischemia, as well 
predicting the final clinical outcome176. Sobesky et al. assessed CTP-CBF thresholds for 
distinguishing viable and non-viable penumbra, and determined that ischemic regions 
with >66% reduction in CBF had >95% positive predictive value for eventual infarction 
(95% specificity)177. In addition, Sobesky et al. determined that ischemic regions with 
<50% reduction in CBF had >90% positive predictive value for tissue survival (95% 
sensitivity)177. These CTP-CBF thresholds may be more precise than MR DWI/MTT 
mismatch in delineating reversible and irreversible ischemia. However, it should be noted 
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that >75% reduction in CBF is required for accurate visual identification of the CBV core 
corresponding to the non-viable penumbra177. 
Magnetic resonance sequences utilize T2* perfusion-weighted images (PWI), 
which are based on the use of a non-diffusible, gadolinium-based contrast agent, to 
generate CBF, CBV, and MTT maps165. As highlighted in Figure 21, penumbra is 
identified as the area of PWI-DWI mismatch178-181. At the expense of spatial resolution, 
PWI includes imaging of the whole brain, while CTP can only image, albeit at a higher 
resolution, 2-4-cm-thick slabs per contrast bolus165. When combined with a package of 
MR imaging sequences, PWI is particularly useful in the evaluation of the current, 
hemodynamic state of the cerebral parenchyma, which assists with patient management. 
 
Figure 21: Ischemic Penumbra by Magnetic Resonance Perfusion181. Relative MTT 
images demonstrate hypoperfusion of the complete right MCA territory. Relative CBV 
images demonstrate a core of tissue with decreased cerebral blood volume. Overlaid on 
CBF images, the red region highlights the initial infarct volume, while the green region 
highlights the final infarct volume, indicating expansion into the ischemic penumbra. 
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A number of studies have used MRP in an attempt to predict the evolution of 
infarction, as well as the clinical outcome. Schlaug et al. determined that an initial 47% 
relative CBV (rCBV) reduction, and 37% relative CBF (rCBF) reduction characterized 
the region of penumbra that eventually infarcted181. It was hypothesized that severe 
reduction of these perfusion parameters characterized the ischemic core. Other groups 
have evaluated different MRP parameters and thresholds for delineation of the ischemic 
penumbra and core. Neumann-Haefelin et al. concluded that a ≥6 second time to peak 
delay predicted the area of lesion enlargement182. In addition, Thijs et al.183 and Parsons et 
al.184 concluded that MTT delays between 4 and 6 seconds predicted the area of infarct 
expansion. However, when assessing the correlation between hyperacute DWI/PWI 
lesion volumes and functional outcome, Schellinger et al. found that such a relationship 
was not statistically significant185. Therefore, in the hyperacute setting, PWI-DWI 
mismatch overestimates the final infarct volume and represents the worst-case scenario if 
early recanalization of the occluded vessel is not achieved after stroke onset. 
 More recent studies have evaluated MR PWI/DWI mismatch as a selection 
criteria for treatment. The Diffusion-Weighted Imaging Evaluation for Understanding 
Stroke Evolution (DEFUSE)171 study, enrolled patients with a small core and large 
penumbra mismatch pattern. Patients with this mismatch pattern demonstrated a greater 
clinical response to early reperfusion186. The Desmoteplase in Acute Ischemic Stroke 
(DIAS) I & II186,187 studies evaluated advanced CT and MR imaging for intravenous 
desmoteplase, a plasminogen activator derived from vampire bat saliva, and found a 
favorable trend in MR-selected patients. Phase III trials may expand on this trend.	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DISCUSSION 
 
In 1996, the US Food and Drug Administration officially approved intravenous 
recombinant tissue-type plasminogen activator for use in acute ischemic stroke patients 
who present within 3 hours from symptom onset72. Based on inclusion and exclusion 
criteria used in the NINDS69 and ECASS70 t-PA stroke trials, the US FDA released 
guidelines, which indicated that in order to receive intravenous t-PA, a baseline CT scan 
was required to rule out acute ICH or SAH. Current guidelines released by the US FDA 
and American Heart Association Stroke Council require an acute imaging technique, such 
as CT or MRI, sensitive to the presence of hemorrhage72. In 2013, the AHA Stroke 
Council released guidelines, which contained the following suggestion: “In most 
instances, NECT will provide the necessary information to make decisions about 
emergency management”72. Today, NECT remains the most popular imaging modality in 
the setting of acute ischemic stroke. The widespread use of NECT in the acute setting has 
been confirmed by a recent study, “International Survey of Acute Stroke Imaging 
Capabilities,” which was conducted by the Stroke Imaging Repository (STIR) and Virtual 
International Stroke Trials Archive (VISTA)-Imaging Investigators188. Wintermark et al. 
received responses from a total of 223 clinical sites, ranging from Africa, Europe, Asia, 
Australia, and North and South America. Of the total 223 sites, 185 reported the type of 
imaging modalities used in the setting of acute stroke188. As highlighted by Figure 22, 
roughly 72% and 80% of reporting sites across the world and North America, 
respectively, utilize CT for acute imaging of stroke patients189. 
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Figure 22: Acute Imaging Modality (CT & MRI) for Stroke Work-Up Across 
Various Regions189. Of the 185 reporting clinical sites, ~72% utilize CT as the primary 
imaging modality for acute ischemic stroke. Asia is the only country to utilize MRI 
(~75%) as the primary means of imaging acute ischemic stroke. 
 
Strong justification exists for the use of non-contrast-enhanced computed 
tomography in not only the United States, but also in the entire world. NECT is safe, fast, 
increasingly available, and affordable. In addition, NECT is not limited by MRI 
contraindications, such as clinically unstable patients, and patients with claustrophobia, 
metallic implants (pacemakers, defibrillators, surgical clips, ferromagnetic orthopedic 
hardware, etc.), or incompatible prosthetic heart valves. Due to these contraindications, 
each patient needs to be screened to enter an MRI scanner – a potentially time-consuming 
process that is not required for NECT. Acquisition of NECT images is very rapid, and 
therefore, is not prone to the motion artifacts typically found on MR images when 
scanning a non-compliant patient. 
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The strongest argument for the use of computed tomography in the setting of 
hyperacute ischemic stroke is based on the amount of time it takes to acquire the 
necessary images. On a multidetector scanner, NECT images can be acquired in as little 
as 1-2 minutes165. Time is so important in evaluating potential stroke patients because of 
the old adage, ‘time is tissue.’ Saver et al. recently analyzed over 58,000 t-PA-treated 
patients from numerous clinical trials, and concluded there is strong correlation between 
the time to treatment and the magnitude of clinical benefit190. The clinical benefit 
included a reduced rate of mortality and symptomatic ICH, as well as a higher rate of 
functional independence at discharge190. These findings supported a prior, quantitative 
study, which estimated that 1.9 million neurons and 14 billion synapses are lost every 
minute during an ischemic event191. Compared to the normal aging process of the brain 
and its associated rate of neuron loss, an ischemic brain ages 3.1 weeks per minute. These 
calculations were then extrapolated out, where an estimated 120 million neurons and 830 
billion synapses are lost per hour, which equates to an ischemic brain aging 3.6 years. In 
addition, an estimated 1.2 billion neurons would be lost during a 10-hour ischemic event, 
which is the average duration a non-lacunar stroke takes to complete evolution. Given the 
typical duration of such an ischemic event, the ischemic brain would age an estimated 36 
years191. 
In response to the growing evidence that the degree of functional recovery is 
dependent on the time to treatment, a consensus panel organized by NINDS and the AHA 
Stroke Council set forth guidelines that highlight important time-points, which can be 
found in Appendix XII, for the treatment of ischemic stroke patients72. The most 
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important goal within these guidelines is a door-to-needle time (DTNT) ≤60 minutes, 
with ≥80% compliance. However, after an analysis of the AHA Get With the Guidelines 
– Stroke Program database, only 29.1% of treated stroke patients have a DTNT ≤60 
minutes (median DTNT of 75 minutes)192. In addition, evaluation of the multinational 
registry, Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis 
Register, revealed a median DTNT of 65 minutes193. In response to these findings, the 
American Heart Association/American Stroke Association created the “Target: Stroke” 
initiative in order to boost the percentage of patients treated under 60 minutes194. Target: 
Stroke is a national quality improvement initiative focused on identifying and 
implementing strategies that reduce door-to-needle times. The original goal of the 
initiative was to have ≥50% of patients treated within 60 minutes194. Following this 
initiative, data within the AHA Get With the Guidelines – Stroke Program database 
indicates an increase from 29.6% (Q4 2009) to 53.3% (Q3 2013; P<0.0001) of DTNTs 
≤60 minutes195. During this time frame, median DTNTs decreased from 74 to 59 minutes 
(P<0.0001) and the percentage of participating hospitals treating ≥50% of patients ≤60 
minutes increased from 15.6% to 46.7% (P<0.0001)195. While these new figures indicate 
a vast improvement on DTNTs, it is still clear that not enough patients are receiving 
treatment within the recommended time window, despite CT serving as the primary 
imaging modality in the acute setting. 
While NECT still remains the most popular imaging modality, there has been an 
increased prevalence of routine vascular and CT perfusion imaging in hyperacute 
ischemic stroke patients. As part of the standard assessment for intravenous t-PA 
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treatment, 46% of participating sites in the STIR/VISTA international survey routinely 
obtain vascular imaging, and 30% routinely obtain CT perfusion imaging188. While 
NECT typically takes only 1-2 minutes, the addition of CTA and CTP adds an additional 
2-10 minutes to sequence acquisition196. Therefore, the addition of CTA and CTP makes 
CT imaging comparable to MRI. In the emergent assessment of acute stroke patients, 
Schellinger et al. demonstrated that diagnostic MR imaging, which included DWI, GRE, 
FLAIR, intracranial MRA, and MRP, could be performed in 10 minutes197. If 
approximately 10 minutes will be used for hyperacute imaging, then the diagnostic yield 
of the MR sequences suggest that MRI should be the used as the primary imaging 
modality for the assessment of ischemic stroke patients. 
In the emergent assessment of a stroke patient, MR diffusion-weighted images are 
clearly superior in detecting hyperacute ischemic lesions, as supported by numerous 
MR/CT comparative studies112,134,198. DWI sequences provide physical proof of an 
ischemic event, as well as offer information about the size, location, and severity of the 
ischemic lesion. In addition, a prospective comparison between baseline MRI and CT 
scans revealed that image readers identified ischemic lesions three times more often on 
DWI than NECT199. After evaluating all of these studies, the Therapeutics and 
Technology Assessment Subcommittee of the American Academy of Neurology (AAN) 
released an evidence-based guideline, which recommended the use of MRI as the initial 
imaging modality in order to obtain the most accurate diagnosis of ischemic stroke97. Dr. 
Peter Schellinger, lead author of the AAN guideline, advocates for MRI because “the 
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more information you have, the better you are positioned to understand the patient’s 
problem, and having more data allows us to make more accurate prognostications”200. 
As indicated in the AAN recommendation for imaging of acute ischemic stroke, 
the predominant argument against the use of NECT in the emergent setting is the lack of 
information it can provide to stroke physicians97. In most cases, NECT simply rules out 
acute ICH and SAH72. Even if cerebral signs of infarction are present within the first few 
hours of ischemia, the observers’ ability to detect these subtle, early signs on NECT is 
highly inconsistent120,121. Without early signs of ischemia on imaging, the physician’s 
diagnosis is dependent on only clinical observations, while critical treatment decisions 
become dependent on the time last seen normal, as reported by either the terrified patient, 
or stressed family members. In this scenario, complications arise when the patient 
presents with aphasia, confusion, or depression of consciousness that results in an 
inability to give an accurate history, or when family members are unavailable during the 
short treatment window. This lack of information, or incorrect information provided to 
the physician, has led to the t-PA treatment of non-stroke patients, known as stroke 
mimics. 
Numerous clinical stroke centers, which utilize CT as the primary imaging 
modality, have reported treating potential stroke patients who later demonstrate no 
evidence of a stroke on a follow-up MRI. These centers report that up to 17-26% of t-PA-
treated patients lack evidence of an ischemic event, and that 7-11% are classified as a 
‘complete resolution/aversion’ of stroke201-205. In a recent study, Freeman et al. 
determined that complete stroke aversion is rare, occurring in only 0.9% of patients, and 
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that the most likely scenario is that these clinical stroke centers are actually treating 
stroke mimics142. Treatment of stroke mimics, which can include seizure, complicated 
migraine, or conversion disorder, is not uncommon. The proportion of t-PA-treated stroke 
mimics is highly variable, ranging from 1.4-26% in hospital-based registers201-205,206-208. 
Treatment of these stroke mimics with intravenous t-PA remains acceptable, as long as 
the complication rate remains low. However, in a recent, multicenter observational cohort 
study, the frequency of symptomatic ICH in t-PA treated stroke mimics was 1.0% (95% 
confidence interval)208. This rate may seem low, but the reported frequency of 
symptomatic ICH in stroke patients who received placebo in the NINDS and ECASS t-
PA stroke trials was 0.6% and 2.3%, respectively69,70. It is unacceptable to approve of the 
use of t-PA in stroke mimics, considering the frequency of symptomatic ICH is 
comparable between a t-PA-treated group with no neurological damage and a placebo-
treated group with cerebral ischemia. Therefore, in order to eliminate the unnecessary 
treatment of stroke mimics, acute MRI should be the primary imaging modality. 
Gradient recalled echo MR sequences and CT are both effective at identifying 
acute hemorrhage. A significant difference between the two imaging techniques is that 
GRE, unlike CT, can detect old, asymptomatic cerebral hemorrhages, known as 
microbleeds108. Detection of cerebral microbleeds is essential in the assessment of a 
stroke patient because these asymptomatic hemorrhages are indicative of small-vessel 
disease and increase the likelihood of future ICH209-211. It has been suggested that cerebral 
microbleeds represent an increased risk of ICH following intravenous thrombolysis, but 
further studies are required to clarify the true extent of this risk. As part of the DEFUSE 
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study group, Kakuda et al. utilized GRE imaging in the assessment of t-PA eligible 
patients, and determined that there was not a significant increase in ICH in patients with a 
small number of cerebral microbleeds212. However, treatment of patients with a large 
number of microbleeds still remains uncertain. Given that NECT does not detect any 
cerebral microbleeds, and the prevalence of these asymptomatic hemorrhages ranges 
from 24.4-28.0% in the general population213, it is clear that acute MRI should be the 
initial imaging modality when evaluating a stroke patient for potential thrombolysis. 
The true power of MRI in the setting of acute ischemic stroke is its ability to 
distinguish patient subgroups that will benefit from those who will not, when receiving 
intravenous t-PA 3-6 hours from symptom onset171. Pooled individual patient-level 
analysis of four clinical trials, specifically ECASS I70, ECASS II214, Alteplase 
Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) 
A215, and ATLANTIS B216, revealed a clinical benefit of t-PA therapy within the 3-4.5 
hour window217. This clinical benefit included an increased rate of excellent outcome, as 
well as an overall improvement in outcome across the entire range of post-stroke 
disability217. As part of the DEFUSE study group, Albers et al.171 utilized DWI, PWI, 
MRA, T1, and GRE sequences to investigate the clinical response to early reperfusion in 
patients treated within the 3-6 hour window. Albers et al. concluded that MRI is effective 
at distinguishing patients with a “Malignant Profile,” which is defined as a baseline DWI 
lesion ≥100 milliliters (mL) and/or a PWI lesion ≥ 100 mL, from those without a 
Malignant Profile, referred to as a “Target Mismatch Profile”171. Such a distinction is 
significant because early reperfusion in patients with a Target Mismatch profile 
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demonstrated a favorable clinical response in 67% of cases, while patients with a 
Malignant Profile demonstrated a high correlation between early reperfusion and fatal 
ICH171. MRI can not only identify the patient subgroups that will benefit the most, but 
also those who would be harmed from reperfusion therapies. 
MRI also plays an essential role in evaluating patients who wake up with stroke 
symptoms, known as wake-up strokes, as it serves as the only imaging modality for 
inclusion in the MR Witness clinical trial. The MR Witness study allows for t-PA 
treatment of wake-up strokes, based on the ‘tissue clock’ determined by specific MR 
sequences218. This clinical trial is important because nearly 25% of ischemic stroke cases 
are unwitnessed, while 16-28% of patients wake-up with stroke symptoms219-222. For the 
acute evaluation of these patients, FLAIR sequences are used to determine the relative 
age of the ischemic lesion. Further eligibility criteria requires the patient be 18-85 years 
old, last known well within 24 hours from triage, and be able to receive intravenous t-PA 
within 4.5 hours from symptom discovery218. In this case, the use of MRI allows for t-PA 
treatment in patients who would otherwise be excluded due to an unknown time of stroke 
onset. 
A final factor to consider when evaluating which imaging modality should be 
used in the setting of acute ischemic stroke is the patient’s safety within the MRI and CT 
scanner. In both CE-MRA/MRP and CTA/CTP, the use of contrast has been associated 
with a low risk of nephrotoxicity. In CE-MRA/MRP, the use of gadolinium-based 
contrast agents has been linked to nephrogenic systemic fibrosis, but such reactions are 
uncommon in the absence of advanced renal failure (glomerular filtration rate >30 
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mL·min-1.73·m-2)223,224. In CTA/CTP, iodine-based contrast agents resulted in a 3% 
incidence rate of nephropathy, but the use of iso-osmolar or low-osmolar contrasts have 
minimized the associated risk225-227. Iodinated contrast can also interact with Metformin, 
an oral antidiabetic drug, to produce lactic acidosis in the presence of renal failure228. 
While both imaging modalities carry a risk of contrast-induced nephropathy, only CT 
exposes the patient to ionizing radiation. This type of radiation can liberate atomic 
particles (electron, proton or neutron), which can alter chemical bonds and/or generate 
highly reactive molecules165. For an adult, the recommended limit of radiation exposure 
per year is 50 millisieverts (mSv)229, and yet the dose per CT scan can be 2-10 mSv165. 
Given no contraindications, MRI is the safest imaging modality for acute ischemic stroke. 
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CONCLUSION 
 
MRI is commonly viewed as a superior imaging modality over CT, and yet, there 
are numerous barriers that restrict the wider use of MRI in the acute setting. This is 
highlighted by the fact that 72% of reporting sites in the STIR/VISTA international 
survey are equipped to perform hyperacute MRIs, but only ~28% use MRI in the acute 
setting189. One of the main barriers accounting for the low use of acute MRI is the attitude 
towards the associated cost of MR imaging. The cost of MRI scanners and MR imaging 
is approximately double that of CT imaging230. Additionally, a shift from CT to MRI 
would also require expenses associated with additional technician positions, and 
extensive technician training. A way to counter these additional expenses is to prove that 
MRI demonstrates better long-term cost effectiveness. For example, the average length of 
stay among stroke patients is 5.3 days231. The average cost of hospitalization for an 
ischemic and hemorrhagic stroke is $18,963 and $32,035, respectively232. Given 795,000 
strokes occur per year2, 3.4-6.5% receive acute treatment per year233,234, 1.4-26% of those 
treated are stroke mimics201-205,206-208, and a 1.0% rate of symptomatic ICH among treated 
stroke mimics208, the savings from not treating these stroke mimics alone could be as 
much as $256 million. Hospitals are no longer run by physicians, but rather by business 
administrators, and unless these administrators are convinced that a move from CT to 
MRI is cost effective, any push for change will continue to be hindered. Therefore, a 
prospective study, which compares patients treated by CT versus MRI, is needed in order 
	  60	  	  
to evaluate differences in not only patient outcome, but also the associated in-hospital 
expenditures. 
The second barrier accounting for the low use of acute MRI is the belief that 
patients who are evaluated by this imaging modality cannot be consistently treated within 
60 minutes from triage. The gold standard of CT-based treatment occurs at the Helsinki 
University Central Hospital, where significant improvements in t-PA protocol have 
resulted in a median DTNT of 20 minutes, with 94% of these patients receiving treatment 
within 60 minutes235. However, despite the remarkably low DTNT, more than 60% of the 
patients during the years of the study still had poor outcomes235; this is a critical point 
where the acquisition of clinical information is sacrificed for the sake of speed. A 
solution to this issue is the use of acute MRI, but such a transition would require 
substantial changes from the neurologists, emergency departments, and emergency 
medical services. To make such a change and maintain low DTNTs, clinical stroke 
centers need to implement principles of lean manufacturing, which include routing the 
patient directly to imaging, utilizing a parallel process workflow, and implementing 
point-of-care laboratories236. For example, the NIH Stroke Team, an MRI-based group 
located at Suburban Hospital and Washington Hospital Center, implemented such 
principles. The Screening with MRI for Accurate and Rapid Stroke Treatment (SMART) 
study evaluated DTNTs of patients treated by this group, and determined that >50% of 
patients were treated ≤60 minutes for two consecutive quarters after implementation237, as 
highlighted by Figure 23. This data strongly suggests that any clinical stroke center can 
utilize acute MRI and consistently treat stroke patients within 60 minutes from triage. 
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Figure 23: Percentage of Patients Treated by NIH Stroke Team with DTNT ≤60 
Minutes237. Following implementation of lean manufacturing methodologies (prior to Q3 
2013), the NIH Stroke Team treated >50% of patients within 60 minutes for two 
consecutive quarters. 
 
In 1996, the US Food and Drug Administration officially approved the use of 
intravenous recombinant tissue-type plasminogen activator for the treatment of acute 
ischemic stroke with the requirement that a baseline CT scan be performed to rule out 
acute ICH or SAH. Today, the American Heart Association Stroke Council 
acknowledges that MRI is more sensitive to ischemia, and yet, guidelines released by the 
group suggest that either CT or MRI may serve as the primary, hyperacute imaging 
modality. The AHA recommends that for most cases, non-contrast-enhanced CT scans 
provide sufficient information for medical management decisions72. However, MRI is 
clearly the superior imaging modality for acute stroke patients, as it provides extensive 
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diagnostic information, while simultaneously allowing for timely treatment with 
intravenous t-PA. Therefore, the hope is that clinical guidelines, like those released by the 
AHA Stroke Council, will be modified in regards to imaging of acute ischemic stroke, 
with a shift towards MRI. Without a push for change from the major clinical guidelines, 
there will be no pressure on clinical stroke centers to change their principles on imaging 
acute stroke. Such modifications to the guidelines should include: 
 
1. MRI is the primary imaging modality for acute ischemic stroke. Every patient 
who is eligible for acute therapy should be rapidly screened for MRI. 
i. If the patient does not have a contraindication, proceed to MRI. 
Contraindications are rare, excluding only 10-20% of patients200. 
ii. If the patient does have a contraindication to MRI, proceed to CT. 
2. If the patient cannot be immediately screened, proceed to CT. 
i. The patient should never go to x-ray as part of the screening process. 
3. If the patient is uncooperative (head motion, claustrophobia, etc.) or clinically 
unstable, proceed to CT. 
4. If there is <30 minutes left in the treatment window, take the patient to CT. 
5. If the patient arrives during off hours (no in-house MRI technician), or if there 
is already a patient in the MRI scanner, who cannot be removed in a timely 
fashion, proceed to CT. 
 
The overall goal of these modifications is to ensure that treating physicians have enough 
information to completely understand the patient’s condition and make the most accurate 
diagnosis. MRI is an essential diagnostic tool in this process, as it helps physicians not 
only identify suitable patients for treatment, but also identify patients whose treatment 
would be unnecessary and potentially dangerous. 	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APPENDIX I: TOAST Classification of Subtypes of Acute Ischemic Stroke57 
 
Large-artery atherosclerosis (embolus/thrombosis)* 
Cardioembolism (high-risk/medium-risk)* 
Small-vessel occlusion (lacune)* 
Stroke of other determined etiology* 
Stroke of undetermined etiology 
a. Two or more causes identified 
b. Negative evaluation 
c. Incomplete evaluation 
*Possible or probable depending on results of ancillary studies 
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APPENDIX II: A-S-C-O Classification of Subtypes of Acute Ischemic Stroke60 
 
Phenotyping Grades of Pathology Level of Diagnostic Evidence 
A: Atherosclerosis 1. Definitely a potential cause of 
the index stroke 
A. Direct demonstration by gold-
standard diagnostic tests or criteria 
S: Small-vessel disease 2. Causality uncertain B. By indirect evidence or less 
sensitive or specific tests or criteria 
C: Cardiac source 3. Unlikely a direct cause of the 
index stroke (but disease is 
present) 
C. By weak evidence 
O: Other cause 
In the absence of disease the grade is 0. In case of insufficient work-up and that the patient cannot be 
graded, the grade is 9. 
 
	  65	  	  
APPENDIX III: National Institutes of Health Stroke Scale72 
Tested Item Title Responses and Scores 
1A Level of consciousness 0 – Alert 
1 – Drowsy 
2 – Obtunded 
3 – Coma/unresponsive 
1B Orientation questions (2) 0 – Answers both correctly 
1 – Answers one correctly 
2 – Answers neither correctly 
1C Response to commands (2) 0 – Performs both tasks correctly 
1 – Performs one task correctly 
2 – Performs neither correctly 
2 Gaze 0 – Normal horizontal movements 
1 – Partial gaze palsy 
2 – Complete gaze palsy 
3 Visual fields 0 – No visual field defect 
1 – Partial hemianopia 
2 – Complete hemianopia 
3 – Bilateral hemianopia 
4 Facial movement 0 – Normal 
1 – Minor facial weakness 
2 – Partial facial weakness 
3 – Complete unilateral palsy 
5 Motor function (arm) 
a. Left 
b. Right 
0 – No drift 
1 – Drift before 5 seconds 
2 – Falls before 10 seconds 
3 – No effort against gravity 
4 – No movement 
6 Motor function (leg) 
a. Left 
b. Right 
0 – No drift 
1 – Drift before 5 seconds 
2 – Falls before 5 seconds 
3 – No effort against gravity 
4 – No movement 
7 Limb ataxia 0 – No ataxia 
1 – Ataxia in one limb 
2 – Ataxia in two limbs 
8 Sensory 0 – No sensory loss 
1 – Mild sensory loss 
2 – Severe sensory loss 
9 Language 0 – Normal 
1 – Mild aphasia 
2 – Severe aphasia 
3 – Mute or global aphasia 
10 Articulation 0 – Normal 
1 – Mild dysarthria 
2 – Severe dysarthria 
11 Extinction or inattention 0 – Absent 
1 – Mild (one sensory modality lost) 
2 – Severe (two modalities lost) 
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APPENDIX IV: Barthel Index238 
Barthel Index 
Feeding 
0 = unable 
5 = needs help cutting, spreading butter, etc. or requires modified diet 
10 = independent 
Bathing 
0 = dependent 
5 = independent (or in shower) 
Grooming 
0 = needs help with personal care 
5 = independent face/hair/teeth/shaving (implements provided) 
Dressing 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zippers, laces, etc.) 
Bowels 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent 
Bladder 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent 
Toilet Use 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping) 
Transfers (bed to chair and back) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent 
Mobility (on level surfaces) 
0 = immobile or < 50 yards 
5 = wheelchair independent, including corners, > 50 yards 
10 = walks with help of one person (verbal or physical) > 50 yards 
15 = independent (but may use any aid) > 50 yards 
Stairs 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent 
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APPENDIX V: Modified Rankin239 and Glasgow Outcome Scales69,240,241 
Modified Rankin Scale (mRS)  Glasgow Outcome Scale 
(modified version – inverse order) 
Score Description Score Description 
0 No symptoms at all 1 Good Recovery: Resumption of 
normal activities even though 
there may be minor 
neurological or psychological 
deficits 
1 No significant disability despite 
symptoms; able to carry out all usual 
duties and activities 
2 Moderate Disability: Disabled 
but independent. Patient is 
independent as far as daily life 
is concerned. The disabilities 
found include varying degrees 
of dysphasia, hemiparesis, or 
ataxia, as well as intellectual 
and memory deficits and 
personality changes 
2 Slight disability; unable to carry out 
all previous activities, but able to 
look after own affairs without 
assistance 
3 Moderate disability; requiring some 
help, but able to walk without 
assistance 
3 Severe Disability: Conscious 
but disabled. Patient depends 
upon others for daily support 
due to mental or physical 
disability or both 
4 Moderately severe disability; unable 
to walk without assistance and 
unable to attend to own bodily needs 
without assistance 
5 Severe disability; bedridden, 
incontinent and requiring constant 
nursing care and attention 
4 Persistent Vegetative State: 
Patient exhibits no obvious 
cortical function 
6 Dead 5 Death 
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APPENDIX VI. US Food and Drug Administration Guidelines for use of Alteplase83 
Inclusion criteria 
• An adult (≥18 years of age) 
• Diagnosis of ischemic stroke with measurable neurological deficit 
• Arrival at Emergency Department in time to be treated within 3 
hours of symptom onset 
Exclusion criteria 
• Evidence of ICH on a base-line CT scan 
• Significant stroke or head trauma within the preceding 3 months 
• Undergone major surgery within previous 14 days 
• History of ICH 
• Systolic blood pressure above 185 mmHg or diastolic blood 
pressure above 110 mmHg 
o Aggressive treatment was required to reduce blood pressure 
• Rapidly improving or minor symptoms 
• Symptoms suggestive of SAH 
• Gastrointestinal hemorrhage or urinary tract hemorrhage within 
previous 21 days 
• Arterial puncture at a non-compressible site within the previous 7 
days 
• Seizure at the onset of stroke 
• Taking anticoagulants or received heparin within the 48 hours 
preceding the onset of stroke 
• Known bleeding diathesis, including but not limited to: 
o Elevated partial-thromboplastin time 
o International normalized ratio (INR) >1.7 
o Prothrombin times >15 seconds 
o Platelet count <100,000/mm3 
• Glucose concentration <50 mg/dL (2.7 mmol/L) or >400 mg/dL 
(22.2 mmol/L) 
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APPENDIX VII. American Heart & Stroke Association Guidelines for Intravenous 
Fibrinolysis72 
Inclusion criteria 
• No modification 
Exclusion criteria 
• Intracranial neoplasm, AVM, or aneurysm 
• Recent intracranial or intraspinal surgery 
• Active internal bleeding 
• CT demonstrates multilobar infarction (hypodensity >1/3 cerebral 
hemisphere) 
Relative exclusion criteria - Recent experience suggests that under some 
circumstances – with careful consideration and weighting of risk to benefit 
– patients may receive fibrinolytic therapy despite 1 or more relative 
contraindications. Consider risk to benefit of intravenous t-PA 
administration carefully if any of these relative contraindications are 
present: 
• Only minor or rapidly improving stroke symptoms (clearing 
spontaneously) 
• Pregnancy 
• Seizure at onset with postictal residual neurological impairments 
• Major surgery or serious trauma within previous 14 days 
• Recent gastrointestinal or urinary tract hemorrhage (within 
previous 21 days) 
• Recent acute myocardial infarction (within previous 3 months) 
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APPENDIX VIII: American Heart & Stroke Association Guidelines for Imaging 
Acute Stroke72 
1. Emergency imaging of the brain is recommended before initiating 
any specific therapy to treat acute ischemic stroke (Class I; Level of 
Evidence A). In most instances, non-contrast-enhanced computed 
tomography (NECT) will provide the necessary information to make 
decisions about emergency management. 
2. Either NECT or MRI is recommended before intravenous 
recombinant tissue plasminogen activator (rtPA) administration to 
exclude ICH (absolute contraindication) and to determine whether 
CT hypodensity or MRI hyperintensity of ischemia is present (Class 
I; Level of Evidence A). 
3. Intravenous fibrinolytic therapy is recommended in the setting of 
early ischemic changes (other than frank hypodensity) on CT, 
regardless of their extent (Class I; Level of Evidence A). 
4. A noninvasive intracranial vascular study is strongly recommended 
during the initial imaging evaluation of the acute stroke patient if 
either intra-arterial fibrinolysis or mechanical thrombectomy is 
contemplated for management but should not delay intravenous rtPA 
if indicated (Class I; Level of Evidence A). 
5. In intravenous fibrinolysis candidates, the brain imaging study should 
be interpreted within 45 minutes of patient arrival in the emergency 
department by a physician with expertise in reading CT and MRI 
studies of the brain parenchyma (Class I; Level of Evidence C). 
6. CT perfusion and MRI perfusion and diffusion imaging, including 
measures of infarct core and penumbra, may be considered for the 
selection of patients for acute reperfusion therapy beyond the time 
windows for intravenous fibrinolysis. These techniques provide 
additional information that may improve diagnosis, mechanism, and 
severity of ischemic stroke and allow more informed clinical decision 
making (Class IIb; Level of Evidence B). 
7. Frank hypodensity on NECT may increase the risk of hemorrhage 
with fibrinolysis and should be considered in treatment decisions. If 
frank hypodensity involves more than one third of the MCA territory, 
intravenous rtPA treatment should be withheld (Class III; Level of 
Evidence A). 
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APPENDIX IX: Axial CT and MRI (T1WI) at Level of Internal Capsule and Basal 
Ganglia99 
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APPENDIX X: Axial CT and MRI (T1WI) at Level of the Midbrain99 
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APPENDIX XI: Axial CT and MRI (T1WI) at Level of Fourth Ventricle and Pons99 
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Appendix XII: Essential Time-Points of Emergency Triage and Initial Evaluation72 
Action Time 
Door to physician ≤10 minutes 
Door to stroke team ≤15 minutes 
Door to CT initiation ≤25 minutes 
Door to CT interpretation ≤45 minutes 
Door to drug (≥80% compliance) ≤60 minutes 
Door to stroke unit admission ≤3 hours 
 
 
 
  
	  75	  	  
LIST OF JOURNAL ABBREVIATIONS 
 
Acad Emerg Med   Academic Emergency Medicine 
Acta Neurol Scand   Acta Neurologica Scandinavica 
AJNR Am J Neuroradiol  American Journal of Neuroradiology 
Am J Manag Care   American Journal of Managed Care 
Ann Emerg Med   Annals of Emergency Medicine 
Ann Neurol    Annals of Neurology 
Bull World Health Organ  Bulletin of the World Health Organization 
Can Assoc Radiol J   Canadian Association of Radiologists Journal 
Cerebrovasc Dis   Cerebrovascular Diseases 
CMAJ     Canadian Medical Association Journal 
Cochrane Database Syst Rev  Cochrane Database of Systemic Reviews 
Curr Atheroscler Rep   Current Atherosclerosis Reports 
Eur Neurol    European Neurology 
Evid Rep Technol Assess (Summ) Evidence Report/Technology Assessment 
(Summary) 
Health Aff (Millwood)  Health Affairs (Millwood) 
Health Promot Pract   Health Promotion Practice 
J Am Coll Cardiol   Journal of the American College of Cardiology 
J Cereb Blood Flow Metab  Journal of Cerebral Blood Flow & Metabolism 
J Clin Neurosci   Journal of Clinical Neuroscience 
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J Comput Assist Tomogr  Journal of Computer Assisted Tomography 
J Digit Imaging   Journal of Digital Imaging 
J Emerg Med    Journal of Emergency Medicine 
J Neuroimaging   Journal of Neuroimaging 
J Neurointerv Surg   Journal of Neurointerventional Surgery 
J Neurol    Journal of Neurology 
J Neurol Neurosurg Psychiatry Journal of Neurology, Neurosurgery & Psychiatry 
J Neurol Sci    Journal of the Neurological Sciences 
J Stroke Cerebrovasc Dis  Journal of Stroke and Cerebrovascular Diseases 
J Thromb Haemost   Journal of Thrombosis and Haemostasis 
JAMA     Journal of the American Medical Association 
Lancet Neurol    Lancet Neurology 
Magn Reson Imaging Clin N Am Magnetic Resonance Imaging Clinics of North 
America 
Mayo Clin Proc   Mayo Clinic Proceedings 
Md State Med J   Maryland State Medical Journal 
N Engl J Med    New England Journal of Medicine 
Natl Vital Stat Rep   National Vital Statistics Reports 
Neurocrit Care   Neurocritical Care 
Neuroimaging Clin N Am  Neuroimaging Clinics of North America 
Neurol Neurochir Pol   Neurologia i Neurochirurgia Polska 
Neurol Res    Neurological Research 
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Radiol Clin North Am  Radiologic Clinics of North America 
Rev Cardiovasc Med   Reviews in Cardiovascular Medicine 
Vasc Health Risk Manag  Journal of Vascular Health and Risk Management  
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